129 related articles for article (PubMed ID: 29275078)
1. Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinoma.
Stahl JM; Damast S; Bledsoe TJ; An Y; Verma V; Yu JB; Young MR; Lester-Coll NH
Brachytherapy; 2018; 17(2):399-406. PubMed ID: 29275078
[TBL] [Abstract][Full Text] [Related]
2. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of the treatment for intermediate risk endometrial cancer: postoperative brachytherapy vs. observation.
Fanning J; Hoffman ML; Andrews SJ; Harrah AW; Feldmeier JJ
Gynecol Oncol; 2004 Jun; 93(3):632-6. PubMed ID: 15196856
[TBL] [Abstract][Full Text] [Related]
4. Influence of robotic-assisted laparoscopic hysterectomy on vaginal cuff healing and brachytherapy initiation in endometrial carcinoma patients.
Stahl JM; Park HS; Silasi DA; Azodi M; Damast S
Pract Radiat Oncol; 2016; 6(4):226-232. PubMed ID: 27364883
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer.
Deshmukh AA; Shirvani SM; Lal L; Swint JM; Cantor SB; Smith BD; Likhacheva A
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059428
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of 3D image-guided brachytherapy compared with 2D brachytherapy in the treatment of locally advanced cervical cancer.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Brachytherapy; 2015; 14(1):29-36. PubMed ID: 25443528
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer.
Rankins NC; Secord AA; Jewell E; Havrilesky LJ; Soper JT; Myers E
Gynecol Oncol; 2007 Aug; 106(2):388-93. PubMed ID: 17509672
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Laparoscopic Hysterectomy With Morcellation Compared With Abdominal Hysterectomy for Presumed Myomas.
Rutstein SE; Siedhoff MT; Geller EJ; Doll KM; Wu JM; Clarke-Pearson DL; Wheeler SB
J Minim Invasive Gynecol; 2016 Feb; 23(2):223-33. PubMed ID: 26475764
[TBL] [Abstract][Full Text] [Related]
11. Intravaginal 1-week high-dose-rate brachytherapy alone for Stages I-II endometrial cancer.
Martínez-Monge R; Nagore G; Cambeiro M; Garrán C; Villafranca E; Jurado M
Brachytherapy; 2007; 6(3):195-200. PubMed ID: 17681240
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases.
Lester-Coll NH; Dosoretz AP; Magnuson WJ; Laurans MS; Chiang VL; Yu JB
J Neurosurg; 2016 Dec; 125(Suppl 1):18-25. PubMed ID: 27903191
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.
Dunn EF; Geye H; Platta CS; Gondi V; Rose S; Bradley KA; Anderson BM
Gynecol Oncol; 2014 Jun; 133(3):494-8. PubMed ID: 24657301
[TBL] [Abstract][Full Text] [Related]
14. Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing.
Ning MS; Klopp AH; Jhingran A; Lin LL; Eifel PJ; Vedam S; Lawyer AA; Olivieri ND; Guzman AB; Incalcaterra JR; Mesko SM; Pezzi TA; Boyce-Fappiano DR; Shaitelman SF; Frank SJ; Thaker NG
Brachytherapy; 2019; 18(4):445-452. PubMed ID: 30992185
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant radiotherapy in Stage II endometrial carcinoma: Is brachytherapy alone sufficient for local control?
Paydar I; DeWees T; Powell M; Mutch DG; Grigsby PW; Schwarz JK
Brachytherapy; 2015; 14(4):427-32. PubMed ID: 25911995
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer.
Orellana TJ; Kim H; Beriwal S; Bhargava R; Berger J; Buckanovich RJ; Coffman LG; Courtney-Brooks M; Mahdi H; Olawaiye AB; Sukumvanich P; Taylor SE; Smith KJ; Lesnock JL
Gynecol Oncol; 2022 Jan; 164(1):129-135. PubMed ID: 34740462
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer.
Hayman JA; Hillner BE; Harris JR; Weeks JC
J Clin Oncol; 1998 Mar; 16(3):1022-9. PubMed ID: 9508186
[TBL] [Abstract][Full Text] [Related]
18. Predictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinoma.
Park HS; Ratner ES; Lucarelli L; Polizzi S; Higgins SA; Damast S
Brachytherapy; 2015; 14(4):464-70. PubMed ID: 25887343
[TBL] [Abstract][Full Text] [Related]
19. Economic impact of decreasing the fraction number in vaginal cuff brachytherapy: A direct cost analysis.
Zhang Y; Rovirosa A; Ascaso C; Herreros A; Torne A; Li Y; Biete A; Sánchez J
Brachytherapy; 2020; 19(1):60-65. PubMed ID: 31587986
[TBL] [Abstract][Full Text] [Related]
20. How much is another randomized trial of lymph node dissection in endometrial cancer worth? A value of information analysis.
Havrilesky LJ; Chino JP; Myers ER
Gynecol Oncol; 2013 Oct; 131(1):140-6. PubMed ID: 23800699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
